VOZMOZhNOSTI DIBIKORA V KORREKTsII METABOLIChESKIKh I SOSUDISTYKh NARUShENIY U BOL'NYKh KhRONIChESKOY SERDEChNOY NEDOSTATOChNOST'Yu I SAKhARNYM DIABETOM 2 TIPA


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents the results of evaluation of effect of taurine in the combined treatment of chronic heart failure (CHF) on carbohydrate and lipid metabolism, insulin resistance, heart rate variability, systolic and diastolic function of the heart and vascular elastic properties and parameters of microcirculation (MC). The high frequency of heart failure and type 2 diabetes mellitus (DM2), poor prognosis and poor quality of life determine the relevance of the issue of selection of optimal therapy. In diabetes, prevention of target organ damage, including microcirculatory vessels and large arteries, is one of the main goals of treatment. The study included 60 patients of both sexes in the early postinfarction period with functional class (FC) II-III CHF (NYHA) and concomitant DM2. All patients were randomized into two groups of 30 people : Group 1 has received standard therapy of heart failure and standard antidiabetic therapy, and Group 2 has additionally received taurine at the dose of 500 mg twice a day. The effects of 16-week treatment with taurine on FC heart failure, structural and functional cardiac parameters, carbohydrate and lipid metabolism, heart rate variability and MC, elastic properties of the main vessels in CHF patients with concomitant DM2 were evaluated. Inclusion of taurine in the combined treatment of CHF and DM2 has statistical trend to reduce the blood levels of brain natriuretic propeptide, significantly increase the left ventricular ejection fraction, decrease the fasting blood glucose levels and glycosylated hemoglobin levels, decrease the insulin resistance, reduce the LDL and triglyceride levels, leading to normalization of the autonomic cardiac function in particular reduces the number of patients with hypersympathicotonia , promotes clinically significant reduction in stiffness of the vascular wall of the large arteries and significantly improves endothelial function. Against the background of use of taurine, statistically significant increase in the proportion of normocirculation hemodynamic type of microcirculation in patients with CHF and DM2 occurs, attributable to the reducing of the occurrence of spastic type of hemodynamics. Thus, the inclusion of taurine in the combined treatment of patients with CHF and DM2 is justified in early postinfarction period.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Danaei G., Finucane M.M., Lu Y., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2,7 million participants. Lancet. 2011; 378(9785): 31-40.
  2. Kenchaiah S., Narula J., Vasan R.S. Risk factors for heart failure. Med. Clin. North Am. 2004; 88: 1145-72.
  3. Джахангиров Т.Ш. Сердечная недостаточность и сахарный диабет: распространенность, заболеваемость и прогноз. Сердечная недостаточность. 2005; 6(3): 35-8.
  4. Дедов И.И., Александров A.A. Диабетическое сердце: Causa magna. Сердце. 2004; 3(1-13): 5-8.
  5. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. College Cardiology. 2008; 51(2): 93-102.
  6. Lehto S., Ronnemaa T., Pyorala K., Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia. 2000; 43: 148-55.
  7. Montagnani M., Chen H., Barr V.A., Quon M.J. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J. Biol. Chem. 2001; 276: 30392-98.
  8. Кайдашев И.П. NF-kB-сигнализация как основа развития системного воспаления, инсулинорезистентности, липотоксичности, сахарного диабета 2-го типа и атеросклероза. Межд. эндокринол. журнал. 2011; 3(35): 35-40.
  9. Болдуева С.А., Жук В.С., Леонова И.А. и др. Оценка вегетативной регуляции ритма сердца у больных, перенесших острый инфаркт миокарда. Рос. кардиол. журнал. 2002; 5: 13-8.
  10. Salomaa V., Riley W., Kark J.D., et al. Noninsulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. The ARIC Study. Circulation. 1995; 91: 1432-43.
  11. Schaffer S.W., Azuma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can. J. Physiol. Pharmacol. 2009; 87(2): 91-9.
  12. Walczewska M., Marcinkiewicz J. Taurine chloramine and its potential therapeutical application. Przegl. Lek. 2011; 68(6): 334-38.
  13. El Idrissi A., Okeke E., Yan X., et al. Taurine regulation of blood pressure and vasoactivity. Adv. Exp. Med. Biol. 2013; 775: 407-25.
  14. Шестакова М.В., Чугунова Л.А., Шамхалова М.Ш. Опыт применения дибикора при сахарном диабете 2 типа. Сахарный диабет. 2007; 1: 30-1.
  15. Национальные рекомендации ВНОК И ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность. 2010; 11[1(57)]: 1-62.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2011; 5: 1-72.
  17. Бабунц И.В., Мириджанян Э.М., Машаех Ю.А. Азбука анализа вариабельности сердечного ритма. Ставрополь, 2002. 112 с.
  18. Крупаткин А.И., Сидоров В.В. Лазерная допплеровская флоуметрия микроциркуляции крови. М., 2005. 256 с.
  19. Маколкин В.И. Микроциркуляция в кардиологии. М., 2004. 131 c.
  20. Арборишвили Г.Н., Орлова Я.А., Мареев В.Ю., Беленков Ю.Н. Прогностическая роль оценки вариабельности ритма сердца у пациентов с хронической сердечной недостаточностью. Кардиоваск. терапия и профилактика. 2005; 4(4): 361.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>